Medium-vessel Vasculitis Presenting with Myalgia Following COVID-19 Moderna Vaccination

Coronavirus disease 2019 (COVID-19) vaccines have been delivered worldwide to prevent the spread of the disease, and almost all Japanese have received the mRNA vaccines “BNT162b2” (Pfizer-BioNTech) or “mRNA-1273” (Moderna). These vaccines have shown efficacy and safety with only minor adverse drug r...

Descripción completa

Detalles Bibliográficos
Autores principales: Ohmura, Shin-ichiro, Ohkubo, Yusuke, Ishihara, Ryuhei, Otsuki, Yoshiro, Miyamoto, Toshiaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9751726/
https://www.ncbi.nlm.nih.gov/pubmed/36070946
http://dx.doi.org/10.2169/internalmedicine.0293-22
Descripción
Sumario:Coronavirus disease 2019 (COVID-19) vaccines have been delivered worldwide to prevent the spread of the disease, and almost all Japanese have received the mRNA vaccines “BNT162b2” (Pfizer-BioNTech) or “mRNA-1273” (Moderna). These vaccines have shown efficacy and safety with only minor adverse drug reactions. However, some patients develop severe adverse drug reactions, including autoimmune reactions. In addition, systemic vasculitis, mainly small-vessel vasculitis, following COVID-19 vaccination, has been reported. However, only a few investigators have reported medium-vessel vasculitis following vaccination. We herein report a case of medium-vessel vasculitis presenting with myalgia as the initial clinical manifestation following COVID-19 Moderna vaccination.

Ejemplares similares